Premaitha signs up French distributor

MANCHESTER-based Premaitha Health, the developer of a ground-breaking non-invasive prenatal test (NIPT) for Down’s Syndrome, has appointed Adgenix as its exclusive distributor in France.

Dr Stephen Little, chief executive of Premaitha said: “Securing our first French partnership with LaboSud and Adgenix is an important step forward for us as we continue to expand the reach of the IONA test across Europe. Our NIPT test provides more accurate and faster results that will benefit more pregnant women in France.

“We look forward to getting the IONA test up and running at LaboSud with our world class technical support team and training programme. The support of Adgenix as our local distributor has also been a huge benefit in establishing this customer and we hope to continue to develop this and other relationships.”

See article in full at BusinessDesk.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.